Hair loss treatment in Korea: minoxidil to scalp injections

Androgenetic alopecia is progressive, patterned hair thinning driven by how sensitive the follicles are to androgens, and it is the reason most people end up in a Korean hair clinic. Hair loss treatment in Korea sorts into three tiers that are usually presented as one menu: minoxidil, the 5-alpha reductase inhibitors finasteride and dutasteride, and scalp injections. Those tiers do not carry equal evidence, and they do not carry equal regulation. Knowing which tier a clinic is selling, and what each one asks of you over the following year, matters more than which clinic you walk into.

Why is hair loss treatment in Korea a private-pay market?#

Hair loss treatment in Korea is almost entirely private-pay because male- and female-pattern hair loss sits outside the National Health Insurance benefit package, unlike medical hair loss such as alopecia areata. That single fact shapes everything downstream: there is no reference price, clinics set their own fees, and the same three-month course can differ several-fold between two practices on the same street in Gangnam.

The condition itself is common but not universal. A 2001 study in the British Journal of Dermatology examined 10,132 Koreans and found pattern hair loss at Norwood grade III or above in 14.1% of men, a lower prevalence than reported in Caucasian populations. Prevalence rises steeply with age in both sexes, which is why the clinic population skews toward people in their thirties and forties rather than their twenties.

Coverage is under active debate rather than settled. Korea's health ministry named insurance coverage for male-pattern hair loss a policy priority for the second half of 2026, and reporting in June 2026 put an academic estimate of the annual bill at 100 billion to 700 billion won depending on how wide the scope ran. Separately, severe alopecia areata gained reimbursement for the oral drug baricitinib from July 2026 under strict severity criteria and a coverage ceiling. The gap between those two tracks is the practical point: an autoimmune hair loss diagnosis and a pattern hair loss diagnosis are treated differently by the system, so getting the diagnosis right comes before comparing prices.

Foreign patients arriving for dermatology are a large and growing group — Korea recorded more than two million international patients in 2025, with dermatology among the busiest specialties — and hair clinics have adapted their packaging accordingly. The broader pattern of what men book while they are in Korea is covered in our guide to the skin treatments Korean clinics see most from men.

What does minoxidil do, and is 5% better than 2%?#

Minoxidil is a topical solution or foam that widens blood vessels and opens potassium channels in the scalp, which lengthens the growing phase of the hair cycle and enlarges miniaturised follicles. It is the only over-the-counter treatment with regulatory approval for pattern hair loss in most markets, and it works on the follicle rather than on the hormone driving the miniaturisation.

The strength question has a clear answer. A 48-week randomised trial of 393 men published in the Journal of the American Academy of Dermatology in 2002 compared 5% topical minoxidil with 2% and with placebo, and found 5% produced 45% more hair regrowth than 2% by target-area hair count — 18.6 versus 12.7 non-vellus hairs. Response also came earlier with the stronger formulation. The trade was tolerability: itching and local irritation were more common at 5%.

Low-dose oral minoxidil has become a common clinic add-on, and it is prescribed off-label everywhere it is used for hair. Reviews published in 2024 describe typical male dosing in the range of 1 to 5 mg daily, started low and raised over months. Its adverse effects are systemic rather than local: a 2025 narrative review in the Journal of Clinical Medicine reported hypertrichosis — unwanted hair growth elsewhere on the body — in roughly 15% of patients, more often in women and at higher doses, and fluid retention in 1.3% to 10%. Because minoxidil was originally a blood pressure drug, cardiovascular history belongs in the consultation rather than after it.

How do finasteride and dutasteride differ?#

Finasteride and dutasteride are 5-alpha reductase inhibitors, meaning they block the enzyme that converts testosterone into dihydrotestosterone, the androgen that miniaturises susceptible follicles. Finasteride blocks the type II enzyme; dutasteride blocks both type I and type II, which is why it lowers scalp and serum DHT further. Both are taken as a daily tablet, and both address the driver of the condition rather than the follicle's local environment.

Finasteride at 1 mg daily has the longest published record. Five-year multinational data reported in 2002 found men on finasteride were 38 hairs above their baseline count at year five, while the placebo group was 239 hairs below theirs. Standardised photographic assessment rated 48% of treated men improved at five years, with a further 42% unchanged — meaning the more common outcome is holding ground rather than dramatic regrowth. Expectations set around "keeping what is there" match the data better than expectations set around restoration.

Dutasteride is where Korean practice genuinely diverges from American practice. Korea approved dutasteride 0.5 mg for androgenetic alopecia in men in 2009 and required post-marketing surveillance alongside it, so a Korean dermatologist can prescribe it on-label for hair loss where a US prescriber would be going off-label. A randomised trial of 917 men aged 20 to 50 published in the Journal of the American Academy of Dermatology in 2014 found dutasteride 0.5 mg increased hair count and hair width significantly more than finasteride 1 mg at 24 weeks, with adverse events similar in number and severity across the groups. Korean five-year follow-up data published in the Journal of Dermatology in 2024 supported sustained efficacy over that longer horizon.

The side effect conversation deserves specifics rather than reassurance. Pooled one-year trial data in men taking finasteride 1 mg found 4.2% reported at least one sexual adverse effect versus 2.2% on placebo, with decreased libido at 1.8% versus 1.3% and erectile dysfunction at 1.4% versus 0.9%. Most reported symptoms resolve after stopping. Whether a small subset experiences persistent symptoms after discontinuation remains genuinely contested in the literature, and regulators require the possibility to be disclosed. That uncertainty is a reason to have the conversation with a prescriber rather than a reason to dismiss either side of it.

What are scalp injections, and how strong is the evidence?#

Scalp injections deliver a substance directly into the skin of the scalp through fine needles or a mechanical injector, and they are the tier where Korean clinics differentiate themselves commercially. The category covers platelet-rich plasma, peptide-based products marketed as hair fillers, growth-factor mesotherapy cocktails, and exosome preparations. Grouping them under one menu heading hides the fact that their evidence bases are not comparable.

Platelet-rich plasma, or PRP, concentrates a patient's own platelets from a blood draw and injects them into thinning areas. It has the most published support of the injectables: a 2024 systematic review found trials consistently favoured PRP added to topical minoxidil over minoxidil alone at one, three, and five-to-six months, while explicitly rating the certainty of that evidence as low to very low. A 2025 meta-analysis of 43 randomised controlled trials found activated PRP increased hair density compared with placebo. "Probably helps as an add-on, on weak evidence" is a fair summary, and it is a very different claim from the one usually made in a consultation room.

Peptide hair fillers sit a step further out. The widely used Korean-made product is a CE-marked medical device combining cross-linked hyaluronic acid with biomimetic peptides released over about two weeks, given as roughly four sessions at two-week intervals. The efficacy figures quoted for it — around 22% higher hair density and 26% greater thickness at eight weeks — come from a manufacturer-run study of 18 people, which is a promising signal rather than independent confirmation. Exosome preparations are further out again: no exosome product holds regulatory approval as an injectable medicine anywhere, Korea's Ministry of Food and Drug Safety barred the word "exosome" from cosmetic advertising from January 2025, and published Korean case reports describe foreign body granuloma and ischaemic necrosis following intradermal exosome injection.

Prices follow the evidence in reverse. Clinic listings in Korea in 2026 commonly quote PRP sessions in the range of USD 150 to 400 and exosome scalp sessions from about USD 220 to 580, with multi-session packages priced higher, while a month of generic finasteride or topical minoxidil is a fraction of a single injection session. Reading those quotes properly — session counts, what the package includes, what is charged separately — follows the same logic set out in our guide to how to read a Korean clinic quote against US pricing.

What should you settle with a Korean clinic before starting?#

Pattern hair loss treatment is an open-ended relationship rather than a procedure, and that is the mismatch that catches visiting patients. A laser session or a filler appointment finishes when you leave the room; a minoxidil and finasteride regimen only produces the published results if it continues for years, with review along the way. Anyone starting a course in Seoul should settle the continuity question before the first prescription: who supervises month six, and what happens to the plan after the flight home.

That question has a concrete answer to chase. Korean prescriptions are not dispensable abroad, so continuing treatment means a clinician at home willing to take it over, working from records they can read. Asking for the diagnosis, the staging, the drug names and doses, and any baseline scalp photographs in writing turns a Korean consultation into something transferable. The same problem shows up in other months-long prescriptions, and the framing in our guide to oral acne medication in Korea applies here almost unchanged.

Assessment quality is the other thing to judge, and it shows up in the first ten minutes. A clinician who examines the scalp, names the pattern and its grade, distinguishes pattern hair loss from shedding or an autoimmune cause, and explains why a particular tier fits is describing a plan. A consultation that opens with a package price and a session count has skipped the step that decides whether any of it is appropriate. Broader signals for reading a Korean practice are collected in our guide to choosing a dermatology clinic in Korea.

✨ In short#

Hair loss treatment in Korea is a private-pay market built on three tiers with unequal evidence behind them. Minoxidil and the 5-alpha reductase inhibitors carry decades of randomised trial data and have to be taken indefinitely to keep working. Scalp injections are the commercial centre of gravity in Korean clinics and the weakest tier evidentially, with PRP resting on low-certainty evidence, peptide fillers on small manufacturer studies, and exosomes on no approved injectable product at all. The distinctly Korean advantage is regulatory rather than technological: dutasteride has been approved for pattern hair loss there since 2009. The question that predicts a good outcome is who supervises year one, not which clinic you book.